Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Influenza Vaccines | 11 | 2025 | 90 | 2.110 |
Why?
|
Influenza, Human | 12 | 2025 | 191 | 2.100 |
Why?
|
Sepsis | 19 | 2024 | 272 | 2.060 |
Why?
|
Intensive Care Units | 24 | 2024 | 423 | 1.920 |
Why?
|
Respiration, Artificial | 20 | 2023 | 292 | 1.830 |
Why?
|
Hospitalization | 31 | 2025 | 1290 | 1.780 |
Why?
|
Protein C | 10 | 2012 | 29 | 1.280 |
Why?
|
Noninvasive Ventilation | 7 | 2021 | 70 | 1.280 |
Why?
|
Respiratory Insufficiency | 7 | 2021 | 148 | 1.040 |
Why?
|
Critical Care | 12 | 2024 | 397 | 1.020 |
Why?
|
Hospital Mortality | 17 | 2024 | 841 | 1.000 |
Why?
|
Coronavirus Infections | 7 | 2020 | 192 | 0.990 |
Why?
|
Pneumonia, Viral | 7 | 2020 | 205 | 0.980 |
Why?
|
Adult | 74 | 2025 | 15669 | 0.980 |
Why?
|
Middle Aged | 76 | 2025 | 16317 | 0.970 |
Why?
|
United States | 53 | 2025 | 7390 | 0.930 |
Why?
|
Vaccination | 15 | 2025 | 334 | 0.920 |
Why?
|
Humans | 129 | 2025 | 59360 | 0.840 |
Why?
|
Aged | 59 | 2025 | 13416 | 0.820 |
Why?
|
Decision Making | 8 | 2024 | 395 | 0.770 |
Why?
|
Male | 74 | 2025 | 27739 | 0.720 |
Why?
|
Female | 77 | 2025 | 30705 | 0.710 |
Why?
|
Acute Lung Injury | 8 | 2019 | 43 | 0.690 |
Why?
|
Respiratory Syncytial Virus Infections | 3 | 2025 | 34 | 0.660 |
Why?
|
Professional-Family Relations | 7 | 2024 | 89 | 0.660 |
Why?
|
Shock, Septic | 4 | 2018 | 86 | 0.590 |
Why?
|
Critical Illness | 11 | 2023 | 325 | 0.580 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2018 | 57 | 0.570 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2018 | 52 | 0.550 |
Why?
|
Pulmonary Embolism | 1 | 2018 | 170 | 0.500 |
Why?
|
Recombinant Proteins | 7 | 2012 | 689 | 0.460 |
Why?
|
Betacoronavirus | 3 | 2020 | 166 | 0.460 |
Why?
|
Liver Diseases | 3 | 2008 | 138 | 0.450 |
Why?
|
Neuromuscular Blocking Agents | 1 | 2014 | 12 | 0.440 |
Why?
|
Fluid Therapy | 5 | 2023 | 47 | 0.440 |
Why?
|
Communication | 5 | 2019 | 545 | 0.440 |
Why?
|
Practice Patterns, Physicians' | 4 | 2017 | 687 | 0.430 |
Why?
|
Treatment Outcome | 24 | 2023 | 5284 | 0.420 |
Why?
|
Pandemics | 10 | 2023 | 615 | 0.410 |
Why?
|
Young Adult | 15 | 2025 | 4267 | 0.410 |
Why?
|
Adolescent | 20 | 2025 | 5824 | 0.400 |
Why?
|
Blood Group Incompatibility | 1 | 2012 | 10 | 0.390 |
Why?
|
Vital Signs | 1 | 2012 | 11 | 0.390 |
Why?
|
Influenza A Virus, H1N1 Subtype | 2 | 2024 | 86 | 0.390 |
Why?
|
Blood Volume | 1 | 2012 | 42 | 0.380 |
Why?
|
Transfusion Reaction | 1 | 2012 | 44 | 0.380 |
Why?
|
Anti-Infective Agents | 2 | 2010 | 143 | 0.370 |
Why?
|
Length of Stay | 8 | 2021 | 775 | 0.360 |
Why?
|
Proxy | 3 | 2019 | 13 | 0.360 |
Why?
|
Case-Control Studies | 9 | 2024 | 1051 | 0.350 |
Why?
|
Hydroxychloroquine | 2 | 2020 | 19 | 0.350 |
Why?
|
Antibodies, Viral | 3 | 2022 | 292 | 0.350 |
Why?
|
Personnel, Hospital | 2 | 2020 | 41 | 0.350 |
Why?
|
Pregnancy Complications | 2 | 2005 | 364 | 0.350 |
Why?
|
Retrospective Studies | 16 | 2021 | 6071 | 0.340 |
Why?
|
Patient Preference | 3 | 2024 | 78 | 0.340 |
Why?
|
Prospective Studies | 14 | 2024 | 3067 | 0.320 |
Why?
|
Multiple Organ Failure | 5 | 2018 | 43 | 0.310 |
Why?
|
Influenza A Virus, H3N2 Subtype | 3 | 2024 | 26 | 0.310 |
Why?
|
Bias | 3 | 2024 | 108 | 0.310 |
Why?
|
Hemodynamics | 4 | 2008 | 230 | 0.310 |
Why?
|
Lung | 3 | 2018 | 919 | 0.310 |
Why?
|
Severity of Illness Index | 10 | 2022 | 1479 | 0.300 |
Why?
|
HELLP Syndrome | 2 | 2005 | 3 | 0.300 |
Why?
|
Pneumonia | 5 | 2021 | 281 | 0.290 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2005 | 202 | 0.290 |
Why?
|
Logistic Models | 9 | 2021 | 1232 | 0.280 |
Why?
|
Vasoconstrictor Agents | 3 | 2023 | 64 | 0.280 |
Why?
|
Fatty Liver | 2 | 2005 | 98 | 0.270 |
Why?
|
Pre-Eclampsia | 2 | 2005 | 69 | 0.270 |
Why?
|
Physicians | 3 | 2022 | 435 | 0.270 |
Why?
|
Cohort Studies | 11 | 2024 | 2374 | 0.270 |
Why?
|
Hospitals, Teaching | 2 | 2018 | 101 | 0.260 |
Why?
|
Aged, 80 and over | 17 | 2025 | 5128 | 0.260 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 4 | 2021 | 657 | 0.250 |
Why?
|
Shock | 2 | 2008 | 31 | 0.240 |
Why?
|
RNA, Messenger | 7 | 2023 | 1465 | 0.240 |
Why?
|
Vaccines, Synthetic | 5 | 2022 | 68 | 0.240 |
Why?
|
Respiratory Syncytial Virus Vaccines | 1 | 2025 | 21 | 0.230 |
Why?
|
Immunocompromised Host | 2 | 2022 | 100 | 0.220 |
Why?
|
Glucocorticoids | 2 | 2015 | 179 | 0.220 |
Why?
|
Asthma | 3 | 2021 | 453 | 0.220 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2023 | 22 | 0.210 |
Why?
|
Prognosis | 9 | 2023 | 1600 | 0.210 |
Why?
|
Venous Thromboembolism | 1 | 2025 | 141 | 0.210 |
Why?
|
Hypotension | 2 | 2023 | 48 | 0.210 |
Why?
|
Tidal Volume | 2 | 2019 | 37 | 0.210 |
Why?
|
Pulmonary Circulation | 1 | 2003 | 27 | 0.210 |
Why?
|
Neurologic Examination | 1 | 2003 | 52 | 0.210 |
Why?
|
Goals | 1 | 2023 | 88 | 0.210 |
Why?
|
Influenza A virus | 1 | 2024 | 116 | 0.200 |
Why?
|
Bacterial Infections | 1 | 2024 | 140 | 0.200 |
Why?
|
Outpatients | 2 | 2021 | 136 | 0.200 |
Why?
|
Comorbidity | 7 | 2017 | 1078 | 0.200 |
Why?
|
Treatment Failure | 6 | 2021 | 185 | 0.200 |
Why?
|
Family | 3 | 2024 | 229 | 0.200 |
Why?
|
Decision Support Systems, Clinical | 1 | 2022 | 64 | 0.200 |
Why?
|
Emergency Service, Hospital | 3 | 2025 | 1021 | 0.200 |
Why?
|
Trust | 1 | 2022 | 67 | 0.190 |
Why?
|
Clinical Trials as Topic | 3 | 2019 | 441 | 0.190 |
Why?
|
Organ Transplantation | 1 | 2022 | 53 | 0.190 |
Why?
|
Immunization, Secondary | 1 | 2022 | 40 | 0.190 |
Why?
|
Propensity Score | 2 | 2014 | 144 | 0.190 |
Why?
|
Age Factors | 5 | 2012 | 1504 | 0.180 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 178 | 0.180 |
Why?
|
Attitude of Health Personnel | 2 | 2016 | 550 | 0.180 |
Why?
|
Brain Injuries | 1 | 2003 | 135 | 0.180 |
Why?
|
Work | 1 | 2020 | 15 | 0.180 |
Why?
|
Telecommunications | 1 | 2020 | 9 | 0.180 |
Why?
|
Heart | 1 | 2003 | 274 | 0.180 |
Why?
|
Contact Tracing | 1 | 2020 | 14 | 0.180 |
Why?
|
Interleukin-6 | 4 | 2017 | 310 | 0.180 |
Why?
|
Symptom Assessment | 1 | 2020 | 44 | 0.180 |
Why?
|
Risk Factors | 7 | 2020 | 4984 | 0.170 |
Why?
|
Drug Therapy, Computer-Assisted | 2 | 2012 | 10 | 0.170 |
Why?
|
Blood Glucose | 2 | 2008 | 461 | 0.170 |
Why?
|
Body Water | 1 | 2000 | 16 | 0.170 |
Why?
|
Delivery of Health Care | 2 | 2022 | 408 | 0.170 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2025 | 724 | 0.170 |
Why?
|
Databases, Factual | 5 | 2016 | 813 | 0.170 |
Why?
|
Electric Impedance | 1 | 2000 | 35 | 0.170 |
Why?
|
Electronic Health Records | 5 | 2023 | 342 | 0.170 |
Why?
|
Optimism | 1 | 2019 | 5 | 0.160 |
Why?
|
Community-Acquired Infections | 1 | 2020 | 92 | 0.160 |
Why?
|
Systemic Inflammatory Response Syndrome | 3 | 2005 | 41 | 0.160 |
Why?
|
Pulmonary Alveoli | 1 | 2019 | 44 | 0.160 |
Why?
|
Survival Analysis | 8 | 2019 | 555 | 0.160 |
Why?
|
Catheterization, Swan-Ganz | 3 | 2012 | 12 | 0.160 |
Why?
|
Body Composition | 1 | 2000 | 146 | 0.160 |
Why?
|
Interleukin-18 | 1 | 2019 | 71 | 0.160 |
Why?
|
Enteral Nutrition | 3 | 2012 | 54 | 0.160 |
Why?
|
Double-Blind Method | 9 | 2017 | 715 | 0.160 |
Why?
|
Intubation, Intratracheal | 1 | 2021 | 194 | 0.160 |
Why?
|
Patient Care Planning | 1 | 2019 | 84 | 0.150 |
Why?
|
Recovery of Function | 1 | 2020 | 270 | 0.150 |
Why?
|
APACHE | 7 | 2019 | 46 | 0.150 |
Why?
|
Environmental Exposure | 1 | 2020 | 208 | 0.150 |
Why?
|
Triage | 2 | 2018 | 109 | 0.150 |
Why?
|
Seasons | 3 | 2024 | 123 | 0.150 |
Why?
|
Ambulatory Care | 1 | 2020 | 300 | 0.150 |
Why?
|
Ganciclovir | 1 | 2017 | 18 | 0.140 |
Why?
|
Hospitals, Community | 1 | 2018 | 70 | 0.140 |
Why?
|
Inpatients | 1 | 2020 | 291 | 0.140 |
Why?
|
Cross Infection | 2 | 2020 | 149 | 0.140 |
Why?
|
Quality of Life | 2 | 2022 | 1137 | 0.140 |
Why?
|
Advance Directives | 1 | 2017 | 45 | 0.140 |
Why?
|
Time Factors | 7 | 2023 | 3617 | 0.140 |
Why?
|
Cytomegalovirus Infections | 1 | 2017 | 66 | 0.140 |
Why?
|
Cytomegalovirus | 1 | 2017 | 90 | 0.130 |
Why?
|
Insulin | 2 | 2012 | 674 | 0.130 |
Why?
|
Glasgow Coma Scale | 1 | 1996 | 43 | 0.130 |
Why?
|
Acute Disease | 4 | 2019 | 660 | 0.130 |
Why?
|
Sex Factors | 4 | 2012 | 935 | 0.130 |
Why?
|
Health Facility Size | 1 | 2015 | 16 | 0.130 |
Why?
|
Hospitals, Rural | 1 | 2015 | 19 | 0.130 |
Why?
|
Hospitals, Urban | 1 | 2015 | 43 | 0.130 |
Why?
|
Stomach Ulcer | 1 | 1995 | 6 | 0.120 |
Why?
|
Pulmonary Wedge Pressure | 3 | 2011 | 26 | 0.120 |
Why?
|
Cross-Sectional Studies | 5 | 2025 | 2373 | 0.120 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 1996 | 85 | 0.120 |
Why?
|
Wounds and Injuries | 1 | 2017 | 229 | 0.120 |
Why?
|
Central Venous Pressure | 2 | 2012 | 12 | 0.120 |
Why?
|
Water-Electrolyte Balance | 2 | 2011 | 17 | 0.120 |
Why?
|
Truth Disclosure | 1 | 2015 | 56 | 0.120 |
Why?
|
Antiviral Agents | 1 | 2017 | 313 | 0.110 |
Why?
|
Fluorobenzenes | 1 | 2014 | 5 | 0.110 |
Why?
|
Surveys and Questionnaires | 2 | 2018 | 2513 | 0.110 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2010 | 40 | 0.110 |
Why?
|
Pyrimidines | 1 | 2014 | 131 | 0.110 |
Why?
|
Clostridium Infections | 1 | 2014 | 45 | 0.110 |
Why?
|
Stress, Physiological | 1 | 1995 | 185 | 0.110 |
Why?
|
Sulfonamides | 1 | 2014 | 121 | 0.110 |
Why?
|
Influenza B virus | 2 | 2024 | 7 | 0.100 |
Why?
|
Ventilator Weaning | 2 | 2011 | 19 | 0.100 |
Why?
|
Vaccines, Combined | 2 | 2022 | 7 | 0.100 |
Why?
|
Disease Progression | 4 | 2021 | 1122 | 0.100 |
Why?
|
Attitude to Health | 1 | 2015 | 279 | 0.100 |
Why?
|
Decision Support Systems, Management | 1 | 2012 | 2 | 0.100 |
Why?
|
Thromboplastin | 1 | 2012 | 6 | 0.100 |
Why?
|
Programming Languages | 1 | 2012 | 14 | 0.100 |
Why?
|
Respiratory Rate | 1 | 2012 | 14 | 0.100 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 206 | 0.100 |
Why?
|
Brain Ischemia | 1 | 1996 | 399 | 0.100 |
Why?
|
Computers | 2 | 2022 | 49 | 0.100 |
Why?
|
Fever | 1 | 2012 | 63 | 0.100 |
Why?
|
Confidence Intervals | 2 | 2010 | 241 | 0.100 |
Why?
|
gamma-Linolenic Acid | 1 | 2011 | 16 | 0.100 |
Why?
|
Academic Medical Centers | 3 | 2020 | 306 | 0.100 |
Why?
|
Eicosapentaenoic Acid | 1 | 2011 | 14 | 0.100 |
Why?
|
Hospital Administration | 1 | 2012 | 41 | 0.090 |
Why?
|
Docosahexaenoic Acids | 1 | 2011 | 30 | 0.090 |
Why?
|
Oxygen | 2 | 2023 | 313 | 0.090 |
Why?
|
Albuterol | 1 | 2011 | 24 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 450 | 0.090 |
Why?
|
Therapeutics | 1 | 1991 | 6 | 0.090 |
Why?
|
Health Surveys | 1 | 2013 | 298 | 0.090 |
Why?
|
International Classification of Diseases | 1 | 2012 | 132 | 0.090 |
Why?
|
Hyperglycemia | 1 | 2012 | 98 | 0.090 |
Why?
|
Socioeconomic Factors | 4 | 2020 | 741 | 0.090 |
Why?
|
Antibodies | 1 | 2012 | 179 | 0.090 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2011 | 34 | 0.090 |
Why?
|
Energy Intake | 1 | 2012 | 167 | 0.090 |
Why?
|
Health Status | 2 | 2022 | 424 | 0.090 |
Why?
|
Cost of Illness | 1 | 2012 | 156 | 0.090 |
Why?
|
Blood Transfusion | 1 | 2012 | 150 | 0.090 |
Why?
|
Documentation | 2 | 2022 | 127 | 0.090 |
Why?
|
Biological Products | 1 | 2012 | 90 | 0.090 |
Why?
|
Heart Rate | 1 | 2012 | 307 | 0.090 |
Why?
|
Self Report | 2 | 2023 | 359 | 0.090 |
Why?
|
Recombinant Fusion Proteins | 1 | 2012 | 490 | 0.090 |
Why?
|
Pregnancy | 3 | 2005 | 2202 | 0.080 |
Why?
|
Ambulatory Care Facilities | 2 | 2020 | 102 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2011 | 132 | 0.080 |
Why?
|
Rhabdomyolysis | 1 | 1989 | 21 | 0.080 |
Why?
|
Antioxidants | 1 | 2011 | 241 | 0.080 |
Why?
|
Blood Pressure | 1 | 2012 | 495 | 0.080 |
Why?
|
Multivariate Analysis | 2 | 2010 | 902 | 0.080 |
Why?
|
Rupture, Spontaneous | 2 | 2005 | 22 | 0.080 |
Why?
|
Vascular Resistance | 3 | 2003 | 48 | 0.080 |
Why?
|
RNA | 2 | 2023 | 401 | 0.080 |
Why?
|
Pulmonary Artery | 2 | 1987 | 90 | 0.080 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 409 | 0.080 |
Why?
|
Infusions, Intravenous | 4 | 2018 | 164 | 0.080 |
Why?
|
Cocaine | 1 | 1989 | 96 | 0.080 |
Why?
|
Substance-Related Disorders | 2 | 2021 | 682 | 0.080 |
Why?
|
Ethics | 1 | 1988 | 1 | 0.080 |
Why?
|
Ethical Review | 1 | 1988 | 3 | 0.080 |
Why?
|
Ethics Committees, Clinical | 1 | 1988 | 5 | 0.080 |
Why?
|
Ethics Committees | 1 | 1988 | 9 | 0.080 |
Why?
|
Embolism, Amniotic Fluid | 1 | 1988 | 1 | 0.080 |
Why?
|
Castor Oil | 1 | 1988 | 2 | 0.080 |
Why?
|
Follow-Up Studies | 4 | 2019 | 2337 | 0.080 |
Why?
|
Risk Assessment | 4 | 2021 | 1921 | 0.080 |
Why?
|
Internet | 1 | 2012 | 448 | 0.080 |
Why?
|
Human Experimentation | 1 | 1988 | 32 | 0.070 |
Why?
|
Drug Administration Schedule | 4 | 2018 | 283 | 0.070 |
Why?
|
Reproducibility of Results | 4 | 2018 | 1561 | 0.070 |
Why?
|
Ethics Committees, Research | 1 | 1988 | 32 | 0.070 |
Why?
|
Odds Ratio | 1 | 2010 | 745 | 0.070 |
Why?
|
Professional Practice | 1 | 2008 | 22 | 0.070 |
Why?
|
Biomedical Research | 2 | 2012 | 256 | 0.070 |
Why?
|
Qualitative Research | 3 | 2017 | 618 | 0.070 |
Why?
|
Alcohol Withdrawal Delirium | 1 | 1987 | 4 | 0.070 |
Why?
|
Meningism | 1 | 1987 | 2 | 0.070 |
Why?
|
Psychoses, Alcoholic | 1 | 1987 | 2 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2020 | 806 | 0.070 |
Why?
|
Hydrocortisone | 2 | 2012 | 187 | 0.070 |
Why?
|
Hemoglobins | 1 | 2008 | 133 | 0.070 |
Why?
|
Polyethylene Glycols | 1 | 2008 | 165 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 677 | 0.070 |
Why?
|
Budd-Chiari Syndrome | 1 | 2005 | 5 | 0.060 |
Why?
|
Hepatolenticular Degeneration | 1 | 2005 | 6 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2008 | 290 | 0.060 |
Why?
|
Phospholipases A | 1 | 2005 | 11 | 0.060 |
Why?
|
Hepatitis B | 1 | 2005 | 28 | 0.060 |
Why?
|
Acetates | 1 | 2005 | 33 | 0.060 |
Why?
|
Health | 1 | 1985 | 31 | 0.060 |
Why?
|
Cholestasis | 1 | 2005 | 53 | 0.060 |
Why?
|
Hematoma | 1 | 2005 | 68 | 0.060 |
Why?
|
Indoles | 1 | 2005 | 107 | 0.060 |
Why?
|
Sentinel Surveillance | 1 | 2024 | 16 | 0.060 |
Why?
|
Mortality | 1 | 1985 | 155 | 0.060 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2024 | 17 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2010 | 735 | 0.060 |
Why?
|
omega-N-Methylarginine | 1 | 2004 | 8 | 0.060 |
Why?
|
Anticoagulants | 1 | 2008 | 477 | 0.060 |
Why?
|
Nitric Oxide Synthase | 1 | 2004 | 45 | 0.060 |
Why?
|
Patient Acuity | 1 | 2023 | 19 | 0.050 |
Why?
|
Hepatitis C | 1 | 2005 | 143 | 0.050 |
Why?
|
Choice Behavior | 1 | 2024 | 78 | 0.050 |
Why?
|
Cardiac Catheterization | 1 | 1985 | 252 | 0.050 |
Why?
|
Survival Rate | 2 | 2019 | 802 | 0.050 |
Why?
|
Vascular Capacitance | 1 | 2003 | 2 | 0.050 |
Why?
|
Cardiac Volume | 1 | 2003 | 7 | 0.050 |
Why?
|
Virus Diseases | 1 | 2024 | 114 | 0.050 |
Why?
|
Programming, Linear | 1 | 2003 | 1 | 0.050 |
Why?
|
Ventricular Function | 1 | 2003 | 22 | 0.050 |
Why?
|
Advisory Committees | 1 | 2024 | 108 | 0.050 |
Why?
|
Ventricular Pressure | 1 | 2003 | 30 | 0.050 |
Why?
|
Trauma Severity Indices | 1 | 2003 | 35 | 0.050 |
Why?
|
Cause of Death | 1 | 2004 | 210 | 0.050 |
Why?
|
Diastole | 1 | 2003 | 89 | 0.050 |
Why?
|
Immunization | 1 | 2023 | 128 | 0.050 |
Why?
|
Viral Load | 1 | 2023 | 220 | 0.050 |
Why?
|
Transplant Recipients | 1 | 2022 | 31 | 0.050 |
Why?
|
Antibody Formation | 1 | 2022 | 108 | 0.050 |
Why?
|
Syndrome | 1 | 2022 | 170 | 0.050 |
Why?
|
Immunization Schedule | 1 | 2022 | 17 | 0.050 |
Why?
|
Immunocompetence | 1 | 2022 | 20 | 0.050 |
Why?
|
RNA, Viral | 1 | 2023 | 259 | 0.050 |
Why?
|
Language | 1 | 2023 | 133 | 0.050 |
Why?
|
Insurance Claim Review | 2 | 2012 | 72 | 0.050 |
Why?
|
Health Services Research | 1 | 2003 | 265 | 0.050 |
Why?
|
Heart Failure | 2 | 2021 | 853 | 0.050 |
Why?
|
Vaccination Coverage | 1 | 2021 | 7 | 0.050 |
Why?
|
Models, Statistical | 1 | 2003 | 298 | 0.050 |
Why?
|
Health Facilities | 1 | 2021 | 41 | 0.040 |
Why?
|
Plasminogen Activator Inhibitor 1 | 2 | 2012 | 15 | 0.040 |
Why?
|
Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 5 | 0.040 |
Why?
|
Research Design | 2 | 2018 | 555 | 0.040 |
Why?
|
Jejunostomy | 1 | 2000 | 7 | 0.040 |
Why?
|
Jejunum | 1 | 2000 | 14 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2020 | 48 | 0.040 |
Why?
|
Jejunal Diseases | 1 | 2000 | 7 | 0.040 |
Why?
|
Asymptomatic Diseases | 1 | 2020 | 46 | 0.040 |
Why?
|
Personal Protective Equipment | 1 | 2020 | 29 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2020 | 136 | 0.040 |
Why?
|
Risk | 3 | 2005 | 364 | 0.040 |
Why?
|
Medical Records Systems, Computerized | 2 | 2012 | 60 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2021 | 146 | 0.040 |
Why?
|
Antimalarials | 1 | 2020 | 67 | 0.040 |
Why?
|
Fibrinolytic Agents | 1 | 2001 | 163 | 0.040 |
Why?
|
Alprostadil | 1 | 1999 | 6 | 0.040 |
Why?
|
Prevalence | 1 | 2023 | 1252 | 0.040 |
Why?
|
Hospitals | 1 | 2022 | 375 | 0.040 |
Why?
|
Withholding Treatment | 1 | 2019 | 40 | 0.040 |
Why?
|
Nervous System Diseases | 1 | 2021 | 104 | 0.040 |
Why?
|
Psychotic Disorders | 1 | 2021 | 149 | 0.040 |
Why?
|
Vasodilator Agents | 1 | 1999 | 63 | 0.040 |
Why?
|
Liposomes | 1 | 1999 | 100 | 0.040 |
Why?
|
Accidents, Traffic | 1 | 2000 | 148 | 0.040 |
Why?
|
Chronic Disease | 1 | 2022 | 716 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 1025 | 0.040 |
Why?
|
Mental Competency | 1 | 2019 | 55 | 0.040 |
Why?
|
Factor Analysis, Statistical | 1 | 2018 | 98 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2017 | 18 | 0.040 |
Why?
|
Virus Activation | 1 | 2017 | 23 | 0.040 |
Why?
|
Data Collection | 2 | 2012 | 371 | 0.040 |
Why?
|
Drug Carriers | 1 | 1999 | 175 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2019 | 525 | 0.030 |
Why?
|
Obesity | 1 | 2005 | 1166 | 0.030 |
Why?
|
Advance Care Planning | 1 | 2017 | 61 | 0.030 |
Why?
|
Biomarkers | 2 | 2012 | 1306 | 0.030 |
Why?
|
Psychometrics | 1 | 2018 | 362 | 0.030 |
Why?
|
Computers, Handheld | 1 | 2016 | 38 | 0.030 |
Why?
|
Insurance, Health | 2 | 2011 | 133 | 0.030 |
Why?
|
Narration | 1 | 2016 | 42 | 0.030 |
Why?
|
Peptic Ulcer Hemorrhage | 1 | 1995 | 3 | 0.030 |
Why?
|
Incidence | 1 | 2019 | 1237 | 0.030 |
Why?
|
Perception | 1 | 2016 | 167 | 0.030 |
Why?
|
Bronchodilator Agents | 1 | 2015 | 122 | 0.030 |
Why?
|
Social Work | 1 | 2015 | 24 | 0.030 |
Why?
|
Patient Selection | 2 | 2005 | 464 | 0.030 |
Why?
|
Rosuvastatin Calcium | 1 | 2014 | 3 | 0.030 |
Why?
|
Cardiac Output | 2 | 1991 | 27 | 0.030 |
Why?
|
Creatine Kinase | 1 | 2014 | 41 | 0.030 |
Why?
|
Liver Failure | 1 | 2014 | 17 | 0.030 |
Why?
|
Myocardial Infarction | 1 | 2021 | 862 | 0.030 |
Why?
|
Physician-Patient Relations | 1 | 2017 | 396 | 0.030 |
Why?
|
Renal Insufficiency | 1 | 2014 | 65 | 0.030 |
Why?
|
Nurses | 1 | 2015 | 102 | 0.030 |
Why?
|
Hemorrhage | 2 | 2008 | 260 | 0.030 |
Why?
|
Thrombomodulin | 1 | 2012 | 15 | 0.030 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2012 | 101 | 0.020 |
Why?
|
Pulmonary Edema | 1 | 2012 | 28 | 0.020 |
Why?
|
Organ Dysfunction Scores | 1 | 2012 | 19 | 0.020 |
Why?
|
Interleukin-8 | 1 | 2012 | 87 | 0.020 |
Why?
|
Hematuria | 1 | 2012 | 19 | 0.020 |
Why?
|
Stroke | 1 | 2021 | 1127 | 0.020 |
Why?
|
Population Surveillance | 1 | 2013 | 194 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2012 | 97 | 0.020 |
Why?
|
Creatinine | 1 | 2011 | 128 | 0.020 |
Why?
|
Risk Adjustment | 1 | 2011 | 93 | 0.020 |
Why?
|
Economics, Hospital | 1 | 2011 | 14 | 0.020 |
Why?
|
Administration, Inhalation | 1 | 2011 | 145 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2011 | 228 | 0.020 |
Why?
|
Health Expenditures | 1 | 2012 | 113 | 0.020 |
Why?
|
Hospital Departments | 1 | 1990 | 12 | 0.020 |
Why?
|
Anemia | 1 | 2012 | 119 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 705 | 0.020 |
Why?
|
Surgery Department, Hospital | 1 | 1990 | 20 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 446 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2011 | 110 | 0.020 |
Why?
|
Renal Dialysis | 1 | 2011 | 189 | 0.020 |
Why?
|
Hospital Costs | 1 | 2011 | 119 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2011 | 452 | 0.020 |
Why?
|
Gastrointestinal Tract | 1 | 2012 | 170 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2012 | 446 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 1990 | 149 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 1996 | 635 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2011 | 223 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2012 | 1093 | 0.020 |
Why?
|
Therapeutic Human Experimentation | 1 | 1988 | 5 | 0.020 |
Why?
|
Government | 1 | 1988 | 8 | 0.020 |
Why?
|
Respiratory Dead Space | 1 | 2008 | 2 | 0.020 |
Why?
|
Third-Party Consent | 1 | 1988 | 9 | 0.020 |
Why?
|
Control Groups | 1 | 1988 | 12 | 0.020 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 1988 | 5 | 0.020 |
Why?
|
Social Control, Formal | 1 | 1988 | 19 | 0.020 |
Why?
|
Fees and Charges | 1 | 1988 | 18 | 0.020 |
Why?
|
Fetal Death | 1 | 1988 | 12 | 0.020 |
Why?
|
Federal Government | 1 | 1988 | 19 | 0.020 |
Why?
|
Terminally Ill | 1 | 1988 | 17 | 0.020 |
Why?
|
Placebos | 1 | 1988 | 68 | 0.020 |
Why?
|
Government Regulation | 1 | 1988 | 40 | 0.020 |
Why?
|
Animals | 1 | 2006 | 19651 | 0.020 |
Why?
|
Research Subjects | 1 | 1988 | 40 | 0.020 |
Why?
|
Observation | 1 | 2008 | 29 | 0.020 |
Why?
|
Random Allocation | 1 | 1988 | 192 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 1988 | 85 | 0.020 |
Why?
|
Patient Care | 1 | 1988 | 78 | 0.020 |
Why?
|
Vulnerable Populations | 1 | 1988 | 84 | 0.020 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1988 | 138 | 0.020 |
Why?
|
Informed Consent | 1 | 1988 | 138 | 0.020 |
Why?
|
Age Distribution | 1 | 2008 | 249 | 0.020 |
Why?
|
Anuria | 1 | 1987 | 1 | 0.020 |
Why?
|
Oliguria | 1 | 1987 | 1 | 0.020 |
Why?
|
Patients | 1 | 1988 | 103 | 0.020 |
Why?
|
Pericardial Effusion | 1 | 1987 | 16 | 0.020 |
Why?
|
Pharmaceutical Preparations | 1 | 1988 | 117 | 0.020 |
Why?
|
Research | 1 | 1988 | 188 | 0.020 |
Why?
|
Point-of-Care Systems | 1 | 2008 | 120 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2008 | 179 | 0.020 |
Why?
|
Cardiomyopathies | 1 | 2008 | 119 | 0.020 |
Why?
|
Heart Arrest | 1 | 1988 | 161 | 0.020 |
Why?
|
Heart Diseases | 1 | 1988 | 206 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 1987 | 130 | 0.020 |
Why?
|
Motivation | 1 | 1988 | 273 | 0.020 |
Why?
|
Group II Phospholipases A2 | 1 | 2005 | 1 | 0.020 |
Why?
|
Keto Acids | 1 | 2005 | 3 | 0.020 |
Why?
|
Phospholipases A2 | 1 | 2005 | 12 | 0.020 |
Why?
|
Hospital Bed Capacity, 500 and over | 1 | 1985 | 7 | 0.020 |
Why?
|
Drug Costs | 1 | 2005 | 54 | 0.020 |
Why?
|
Europe | 1 | 2005 | 184 | 0.010 |
Why?
|
Phosphates | 1 | 1985 | 90 | 0.010 |
Why?
|
Probability | 1 | 1985 | 166 | 0.010 |
Why?
|
Medical Records | 1 | 1985 | 133 | 0.010 |
Why?
|
Software | 1 | 2008 | 367 | 0.010 |
Why?
|
Inflammation | 1 | 2011 | 1099 | 0.010 |
Why?
|
Patient Admission | 1 | 1985 | 184 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2005 | 589 | 0.010 |
Why?
|
Reference Values | 1 | 2004 | 326 | 0.010 |
Why?
|
Medical Staff, Hospital | 1 | 2003 | 57 | 0.010 |
Why?
|
Forecasting | 1 | 2003 | 219 | 0.010 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2001 | 13 | 0.010 |
Why?
|
Splenectomy | 1 | 2000 | 41 | 0.010 |
Why?
|
Likelihood Functions | 1 | 2000 | 68 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2000 | 116 | 0.010 |
Why?
|
Models, Biological | 1 | 1985 | 1143 | 0.010 |
Why?
|
Necrosis | 1 | 2000 | 140 | 0.010 |
Why?
|
Pancreas | 1 | 2000 | 147 | 0.010 |
Why?
|
Massachusetts | 1 | 1985 | 2002 | 0.010 |
Why?
|
Hypoxia | 1 | 1999 | 112 | 0.010 |
Why?
|
Neoplasms | 1 | 2008 | 1240 | 0.010 |
Why?
|
Pressure | 1 | 1987 | 76 | 0.000 |
Why?
|
Abdomen | 1 | 1987 | 91 | 0.000 |
Why?
|